GERM

ETFMG Treatments Testing and Advancements ETF
*Unless otherwise stated, data provided by FactSet.

GERM Fund Description

GERM tracks a tier-weighted, narrow index of US-listed, global biotech companies that are engaged in the testing and treatments of infectious diseases.

GERM Factset Analytics Insight

GERM provides unique exposure to a subsector of biotech industry. The passively-managed fund holds companies that test and develop treatments against infectious diseases by focusing on companies at the forefront of R&D, vaccines, therapies and testing technologies. Companies included in the index must meet minimum market-cap and liquidity requirements. Also, companies must have an operating company structure, no pass-through securities. Selected stocks are weighted in tiers wherein the top five largest constituents receives 30% weight in the index in aggregate with an equal weight of 6% each, while the remaining securities are weighted by market-cap with 4% single security cap. Companies with market-cap of $15 billion or more are also equally weighted, receiving 10% portion of the portfolio in aggregate. The index is rebalanced and reconstituted every quarter.

GERM MSCI ESG Analytics Insight

ETFMG Treatments Testing and Advancements ETF has an MSCI ESG Fund Rating of BBB based on a score of 5.70 out of 10. The MSCI ESG Fund Rating measures the resiliency of portfolios to long-term risks and opportunities arising from environmental, social, and governance factors. ESG Fund Ratings range from best (AAA) to worst (CCC). Highly rated funds consist of companies that tend to show strong and/or improving management of financially relevant environmental, social and governance issues. These companies may be more resilient to disruptions arising from ESG events.

The fund’s Peer Rank reflects the ranking of a fund’s MSCI ESG Fund Quality Score against the scores of other funds within the same peer group, as defined by the Thomson Reuters Lipper Global Classification. ETFMG Treatments Testing and Advancements ETF ranks in the 35th percentile within its peer group and in the 70th percentile within the global universe of all funds covered by MSCI ESG Fund Ratings.

PERFORMANCE [as of 10/14/21] 1 MONTH 3 MONTHS YTD 1 YEAR 3 YEARS 5 YEARS 10 YEARS
GERM -14.30% -1.46% 23.09% 28.49% -- -- --
GERM (NAV) -10.02% 4.10% 25.34% -- -- -- --
Prime Treatments, Testing and Advancements Index -10.01% 4.27% 25.36% 32.16% -- -- --
N/A -- -- -- -- -- -- --
All returns over 1 year are annualized. All returns are total returns unless otherwise stated.

GERM Summary Data

ETFMG
06/17/20
Open-Ended Fund
0.68%
$59.82M
$817.13K
0.38%
IBB, XBI, FBT, PBE, BBC

GERM Portfolio Data

$47.95B
45.82
5.19
1.00%
12/28/21
80

GERM Index Data

Prime Treatments, Testing and Advancements Index
Tiered
Committee
N/A

GERM Portfolio Management

0.68%
--
--
--

GERM Tax Exposures

20.00% / 39.60%
--
Qualified dividends
No

GERM Fund Structure

Open-Ended Fund
No
Yes
-- / --
N/A
N/A
Low
Daily

GERM Factset Analytics Block Liquidity

As of 10/15/21
5
4
3
2
1

This measurement shows how easy it is to trade a $1 million USD block of GERM. GERM is rated a 4 out of 5.

GERM Tradability

19,001
$817.13K
17,202
$713.65K
0.38%
$0.16
-0.13%
1.20% / -1.17%
None
90.00%
50,000
0.34
0.03%
0.66%
182
$38.93
4

GERM Countries


GERM
Segment Benchmark
82.30%
--
8.18%
--
2.95%
--
2.65%
--
2.60%
--
0.60%
--
0.60%
--
0.07%
--
0.06%
--

GERM Regions


GERM
Segment Benchmark
82.35%
--
11.50%
--
6.15%
--

GERM Economic Development


GERM
Segment Benchmark
97.40%
--
2.60%
--

GERM Performance Statistics

--
--
--
--
0.00%
N/A

GERM MSCI ESG Ratings

5.70 / 10
69.87
35.26
0.13%
--
30.04

GERM Benchmark Comparison Holdings

80
--
--
0.00%

GERM Benchmark Comparison Summary


GERM
Segment Benchmark
80
--
$47.95B
--
45.82
--
5.19
--
0.36%
--
High
High

GERM Benchmark Comparison Market Cap Size


GERM
Segment Benchmark
62.15%
--
23.34%
--
10.96%
--
3.55%
--